Burkitt Lymphoma — Trials

Burkitt Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 27
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–16 of 16 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03223610	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	recruiting	Phase 1 / Phase 2	155	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT06395103	Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)	recruiting	Phase 1 / Phase 2	90	Merck Sharp & Dohme LLCINDUSTRY	23	Sep 17, 2026